T1820000
Trapidil
European Pharmacopoeia (EP) Reference Standard
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Seleccione un Tamaño
50 MG
107,00 €
107,00 €
Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
Solicitar un pedido a granel
Seleccione un Tamaño
Cambiar Vistas
50 MG
107,00 €
About This Item
Fórmula empírica (notación de Hill):
C10H15N5
Número de CAS:
Peso molecular:
205.26
Número MDL:
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
NACRES:
NA.24
107,00 €
Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
Solicitar un pedido a granel
Productos recomendados
grado
pharmaceutical primary standard
familia API
trapidil
fabricante / nombre comercial
EDQM
aplicaciones
pharmaceutical (small molecule)
Formato
neat
temp. de almacenamiento
2-8°C
cadena SMILES
CCN(CC)c1cc(C)nc2ncnn12
InChI
1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
Clave InChI
GSNOZLZNQMLSKJ-UHFFFAOYSA-N
¿Está buscando productos similares? Visita Guía de comparación de productos
Categorías relacionadas
Descripción general
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Aplicación
Trapidil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Acciones bioquímicas o fisiológicas
Antiplatelet agent; competitive inhibitor of PDGF receptor; phosphodiesterase inhibitor, vasodilator
Trapidil is an antiplatelet agent that acts in part as a phosphodiesterase inhibitor and as a competitive inhibitor of the platelet-derived growth factor (PDGF) receptor. Trapidil, with its vasodilator and NO releasing effect may have some potential to diminish the tissue injury. Trapidil suppresses platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell (VSMC) proliferation by inhibiting Raf-1/extracellular signal-regulated kinase (ERK) via cAMP/protein kinase A (PKA). In addn. to cAMP/PKA activation, trapidil inhibits RhoA/ROCK activation.
Envase
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Otras notas
Sales restrictions may apply.
Palabra de señalización
Warning
Frases de peligro
Consejos de prudencia
Clasificaciones de peligro
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
Órganos de actuación
Respiratory system
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.
Si necesita más asistencia, póngase en contacto con Atención al cliente
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Hisao Ogawa et al.
Journal of cardiology, 54(2), 171-182 (2009-09-29)
"Evidence-based medicine (EBM)" implies effective and high quality practice for patients based on well-grounded medical science. The success of clinical trials in Japan is essential to build original evidence specific for Japanese patients. Based on this concept, we have performed
Daniele Iaccarino et al.
Journal of cardiovascular medicine (Hagerstown, Md.), 11(7), 536-543 (2010-01-22)
Drug-eluting stents (DES) have been designed to prevent restenosis, but long-term clinical outcome may be offset by an increased risk of stent thrombosis, which is associated with suboptimal stent implantation or delayed re-endothelialization. DES implantation has also been associated with
Zhi-Wen Zhang et al.
Neurosurgery, 66(4), 728-735 (2010-03-23)
After subarachnoid hemorrhage (SAH), platelet-derived growth factor-BB (PDGF-BB) is secreted in and around the cerebral arteries. To clarify the role of PDGF-BB in the development of vasospasm after SAH, we determined whether PDGF-BB alone can cause long-lasting vasoconstriction of a
Belgin Büyükakilli et al.
Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 13(3), 173-179 (2007-11-06)
Trapidil has been shown to possess the protective effects in the treatment of ischemia and reperfusion injury in the peripheral nervous system. The purpose of this study was to determine the effects of low dose trapidil on peripheral nerve regeneration
Russell T Turner et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 25(7), 1637-1649 (2010-03-05)
Chronic hyperparathyroidism (HPT) is a common cause of metabolic bone disease. These studies investigated the underlying cellular and molecular mechanisms responsible for the detrimental actions of elevated parathyroid hormone (PTH) on the skeleton. Bone biopsies from hyperparathyroid patients revealed an
Filtros activos
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
